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INTRODUCTION
Catheter infection in the management of acute hydro-
cephalus could result in serious consequences such as intellec-
tual deterioration and neurological deficits, including death
in severe cases. Infection rates related with external drainage
of cerebrospinal fluid (CSF) is reported as high as 4-17.2%,
and efforts to reduce catheter-induced infection rates during
CSF drainage have included intravenous antibiotics, local anti-
septics, or lengthening of the subcutaneous catheter (1-3). All
of these efforts during last two decades are still unsuccessful
in significantly reducing catheter-induced infection (4-8). 
It is very difficult to develop a polymer that releases antibi-
otics slowly to reduce catheter-induced infection rates, because
the antibiotic ratio to catheter is limited to less than a few
percent, resulting in the low concentration of releasing anti-
biotic (9, 10). This is because the released quantity of the
antibiotic is variable with time, such as an initial burst, or
terminal dumping effect of the antibiotic and also because
the polymer usually does not endure heat up to 300℃ dur-
ing the catheter molding process of the silicon (11, 12). Com-
plexity of development of these antibiotic-releasing polymers
was resolved with introduction of a simple coating and impreg-
nation method of the catheter with antibiotics or antiseptics
(5, 11-15). Coating of the silicon catheter is relatively simple,
but still complex than impregnation of the catheter in method-
ology and safety (5, 16). The impregnation method is so sim-
ple and effective that some clinical trials have already been
held and entered the commercial market, for the example,
BactisealTM of Codman
� (14, 16).
The authors of this study developed a basic polymeric struc-
ture applicable for a drug-delivery-system that had 1) a high
drug composition of more than 10% in drug-polymer weight
ratio, 2) easy control of the releasing rate by a minor change
of the polymer structure, and 3) release duration of up to more
than 6 months. Here we confirm the in vitro releasing char-
acteristics and anti-bacterial activity, and suggest this to be
new drug-delivery-system applied to CSF drainage catheter
and others. 
MATERIALS AND METHODS
Synthesis of polymer 
Authors synthesized a new nalidixic acid polymer using
diisopropylcarbodiimide, poly (e-caprolactone) diol, and nali-
dixic acid. Boiling temperature of the polymer was 350℃,
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Biodegradable Polymer Releasing Antibiotic Developed for Drainage
Catheter of Cerebrospinal Fluid: In Vitro Results 
The authors developed a biodegradable polymer that releases an antibiotic (nalidixic
acid) slowly and continuously, for prevention of catheter-induced infection during
drainage of cerebrospinal fluid. We investigated the in vitro antibiotic releasing char-
acteristics and bacterial killing effects of the new polymer against E. coli. The novel
fluoroquinolone polymer was prepared using diisopropylcarbodiimide, poly (e-capro-
lactone) diol, and nalidixic acid. FT-IR, mass spectrometry, and elemental analysis
proved that the novel antibacterial polymer was prepared successfully without any
side products. Negative MS showed that the released drug has a similar molecular
weight (M.W.=232, 350) to pure drug (M.W.=232). In high pressure liquid chro-
matography, the released drug and drug-oligomer showed similar retention times
(about 4.5-5 min) in comparison to pure drug (4.5 min). The released nalidixic acid
and nalidixic acid derivatives have antibacterial characteristics against E. Coli, Staphy-
lococcus aureus, and Salmonella typhi, of more than 3 months duration. This study
suggests the possibility of applying this new polymer to manufacture drainage catheters
that resist catheter-induced infection, by delivering antibiotics for a longer period of
more than 1 month.
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and the white powder in room temperature. Depending on
the amount of nalidixic acid, PCL-1250 and PCL-2000 were
developed (Fig. 1). The synthetic process is summarized as
follows: 1.16 g of nalidixic acid and 0.756 g of diisopropyl-
carbodiimide was dissolved in 40 mL of methylene chloride
and stirred at room temperature for 1 hr. After 1 hr, 10 g of
poly (caprolactone) diol (M.W.:1250) was added and stirred
at room temperature for more than 24 hr. The solvent was
evaporated, and the residue was dissolved in tetrahydrofuran
and washed with 1 M NaOH. After drying under reduced
pressure, the product was obtained (13). The authors evalu-
ated the released monomeric structure, including nalidixic
acid from nalidixic polymer, releasing rate, and anti-bacteri-
al activity.
Structural validation with mass spectrometry and HPLC 
Mass spectrometry (Agilent 1100 LC/MSD: LC solvent;
Acetonitle: Ion polarity; positive: Ion source; APCI) was used
to validate the structure of the released drug from the film
associated with the cleavage sites in the drug polymer. Mass
spectrometry was performed at 1 week, 3 weeks, and 6 weeks
after the antibiotic polymer was immersed in 25 mL phosphate
buffer saline (PBS; 0.1 M, NaCl; 0.138 M, KCl; 0.0027 M,
Fig. 2). High pressure liquid chromatography (HPLC) esti-
mated that releasing components were the polymer only,
nalidixic acid, nalidixic polymer 1 week after in pH 7.4 phos-
phate buffer saline (NaCl 0.138 M, KCl 0.0027 M) and nali-
dixic polymer in chloroform (Fig. 3). 
Releasing rate of nalidixic acid from nalidixic acid-loaded
polymer 
For the release study, the drug loaded polymer was immersed
in 25 mL phosphate buffer saline (phosphate buffer; 0.1 M,
NaCl; 0.138 M, KCl; 0.0027 M) containing 0.01 wt % NaN3.
They were allowed to stand in thermostated shaking water
bath at 37℃, 60 rpm. At each interval, the liquid phase was
sampled for analysis, and the solvent in the tube was replaced
with an equal volume of fresh buffer medium for the next
release test. The amount of the released drug was measured
at 330 nm with a UV visible spectrometer, and the cumula-
tive release percent for each sample was calculated (Fig. 4).
Anti-bacterial activity of antibiotic-loaded polymer
The E. coli PI strain was grown in trypticase soy broth (Bec-
ton Dickinson Microbiology Systems, Franklin Lakes, NJ,
Fig. 1. Construction of new antibiotic polymer and its action mech-
anism.
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Fig. 2. Synthesis and 3 dimension structure of nalidixic-polymer
from nalidixic acid and poly (caprolactone) diol. 
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Fig. 3. Mass spectrometric analysis of the released drug. (A) con-
trol of nalidixic acid, (B) control of polymer, (C) nalidixic polymer
at 0 day in PBS buffer, (D) after 1 weeks in PBS buffer, (E) after 3
weeks in PBS buffer, (F) after 6 weeks in PBS buffer. Two major
peaks in (D), (E), and (F) are correspond to the pure drug, nalidixic
acid and nalidixic acid salt which are the major products of degra-
dation and release. Minor peaks in (C), (D), (E), and (F) might be
the degraded products of the drug bounded oligomer in which
the cleavage sites are other than the ester linkage directly attatched
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U.S.A.) at 37℃ for 18 hr, and then adjusted to a concentra-
tion of 0.5 McFarland units (108 colony-forming units/mL)
by using standardized spectrophotometric analysis. A cotton
swab was dipped into the bacterial suspension and then rubbed
in a streaking fashion across the whole surface of a Mueller-
Hinton agar plate (Becton Dickinson Microbiology Systems,
Franklin Lakes, NJ, U.S.A.). The 10  L was taken from 30
mL of normal saline solution in which the drug loaded poly-
mer (10 g) was immersed for a given period (every 2-4 weeks).
After sampling, the whole saline solution was replaced with
a fresh one, and the drug loaded polymer was immersed till
the next sampling. The 10  L taken from 30 mL of normal
saline solution, in which drug loaded polymer (10 g) was im-
mersed for a given period, was diluted four times with nor-
mal saline. Each diluted 10  L was dropped softly onto the
center of the agar plate that had been freshly inoculated with
E. coli. After 10  L drop was dried, the agar plate was incu-
bated at 37℃ for 24 hr. The zone of inhibition was assessed
by measuring the radius of the clear zone of inhibition on the
given dilution ratio. The comparative anti-bacterial activity
was calculated on the basis of first 5 days, from the ratio of
dilution and the radius of zone of inhibition. Each cumula-
tive antimicrobial activity was calculated from comparative
anti-bacterial activities. This assay was performed every 2-4
weeks up to 16 weeks (Fig. 5). 
RESULTS
Structural validation with mass spectrometry and HPLC 
The mass spectrometry showed two high peaks (233.1,
274.0) demonstrating that the pure drug, nalidixic acid, and
nalidixic acid salt were the major products of degradation and
release. Early minor peaks of 90, 104, 127, 146, 174 might
be the degraded products of the drug or oligomer, in which
the cleavage sites are other than the ester linkage directly at-
tached nalidixic acid. Several minor peaks larger than nalidixic
acid (233) at about 7 days might be the drug loaded oligomer
or degraded one (Fig. 3). 
HPLC showed a peak at 5 min for nalidixic acid in PBS,
and no peak within 30 min for polymer in PBS. It showed
various peaks of less than 5 min and multiple overlapped
peaks on 30 min for nalidixic acid loaded polymer in chloro-
form. It also showed a peak of nalidixic acid on 5 min for na-
lidixic acid loaded polymer in PBS for 7 days (Fig. 4). PCL-
1250 and PCL-2000 showed the same results in the mass
spectrometry and HPLC. 
Releasing rate of nalidixic acid from nalidixic acid-loaded
polymer 
The cumulative amount of released nalidixic acid from the
two drug-loaded polymer of PCL-1250 and PCL-2000 was
calculated from the measurement with UV visible spectrom-
eter, and showed 2.1 and 3.3% at 1 week, 3.6% and 5.7%
at 2 weeks, 4.9% and 7.5% at 3 weeks, and 5.5% and 8.7%
at 4 weeks, respectively (Fig. 5). The drug nalidixic acid was
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Fig. 4. Analysis with High Pressure Liquid Chromatography for
polymer, nalidixic acid, nalidixic acid polymer in chloroform and
nalidixic acid polymer after 7 days in PBS buffer pH 7.4.
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Fig. 5. Cumulative drug release from the drug polymer. Drugs are
bounded to poly(caprolactone)[M.W.=1250] and 20 mg of drug
bounded PCL are mixed with 10 g of poly (caprolactone) [M.W.=
42,500]. Released drug % is based on the initial loaded pure drug.
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Fig. 6. Cummulative in vitro antibacterial activity test against E.
coli, S. aureus, and S. typhi that is calculated relatively from the
zone of inhibition in agar plate culture of 10  L of PBS immersed
of nalidixic acid polymer for 5-30 days. 
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released from the drug-loaded polymer beyond 20% for about
40 days without initial burst effect.
Anti-bacterial activity of antibiotic-loaded polymer 
When each anti-bacterial activity of the first 5 days for E.
coli, Staphylococcus aureus, and Salmonella typhi was compared
comparatively, each cumulative anti-bacterial activity of PCL-
2000 for E. coli, Staphylococcus aureus, and Salmonella typhi was
5, 9, 2.4 during next 5 days, 7, 9.5, 3.5 during next 30 days,
15, 17.5, 26.9 during next 20 days, 31, 49.5, 73.5 during
next 20 days, 32, 65.5, 78.5 during next 30 days, and 37.7,
88.4, 85.7 during the last 10 days (Fig. 6). 
DISCUSSION
Bacterial infection is often a major complication to the more
widespread application of polymeric materials in medical
devices (17, 18). A foreign body such as a synthetic bioma-
terial causes the adhesion of microorganisms (18). The attach-
ment of bacteria to a biomaterial surface has been known as
a main factor in the initiation of biomaterial-related infections.
Bacterial adhesion leads to their accumulation and produc-
tion of extracellular polymeric substances. Bacterial growth
in extracellular polymeric substances brings to the formation
of the adhesive ‘biofilms’ and isolates the surface from the sur-
rounding environment (19). The biofilms have been consid-
ered to diminish the activity of antibacterials, phagocytic cells,
humoral antagonists and others (20, 21). Some general etio-
logic agents associated with biomaterial-related infections in-
clude Escherichia coli, Proteus mirabilis, Staphylococcus epidermidis,
Enterococcus faecalis and Candida albicans (7, 13, 19, 22).
The bacterial growths with biofilms are able to resist sev-
eral times of the lethal dose of the antibacterial agent (20, 23).
Many approaches have been developed to make a biomaterial
surface that has an antibiotic activity to reduce bacterial col-
onization and the formation of biofilm. Most of these appro-
aches have been based on surface coating with drug or diffu-
sion-limited systems for the delivery of the pharmacophores.
Two most popular approaches are the coating of a device, such
as a stent or catheter with antibacterial agents via an ionic
bonding technique (25), and the impregnation of the silicon
or urethane catheter with antibacterial solution via a simple
dipping method of physical incorporation of the antibiotics
in the polymer matrix (9, 11, 12). Other methods include
the use of silver (25), and physicochemical surface modifica-
tion (26-28). However, major problems in all these approaches
were the fast or irregular release and the initial burst of antibac-
terial agents, leading to an erroneous infection during the con-
tact (13, 15, 29). 
Consequently, there has been a demand for a new method
to prevent the adhesion of microorganisms. An alternative
can be found in using the antimicrobial polymer that contains
the antimicrobial agent linked covalently as a monomer into
the backbone structure of the macromolecule. Woo and co-
workers (10) studied a polyurethane copolymer synthesized
using hexane diisocyante, poly (caprolactone) diol, a biodegrad-
able polyester, and ciprofloxacin, a fluoroquinolone antibiotic.
Their study showed that the degradable polyurethane, includ-
ing the fluoroquinolone by covalent linkage, has an ability
to destroy microorganism when released by degradation of
polymer chains by the macrophage-derived enzyme choles-
terol esterase. However, specification of the cleavage sites and
releasing speed of the drug in the drug polymer were not easy
to control (10, 15). 
The authors of this study developed a new polymeric deliv-
ery system of slow releasing of drugs that has been never re-
ported. New features of this delivery system might be that
the drug is water soluble, but the matrix polymer and oligo-
mers are not soluble in water. Since the drug-bounded oligo-
mers are not soluble in water, the drug can be released only
after the bound oligomers are degraded below a certain length.
Also, the mutual compatibility between the matrix and the
oligomer prevents the initial burst effectively. Practically, we
could increase the drug-polymer ratio up to more than 10%
very easily, and change the releasing speed of the drug to 10
months by controlling the water solubility (hydrophobicity)
of the drug and polymer only, without any initial burst (data
not shown). It is suggested that this delivery system could
be applied to the drainage catheter and drug-delivery systems,
for slow and continuous drug delivery probably such as anti-
cancer agents or hormones.
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